ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 11 of 147 for:    tourette's

Safety and Efficacy of Cannabis in Tourette Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03247244
Recruitment Status : Recruiting
First Posted : August 11, 2017
Last Update Posted : May 3, 2018
Sponsor:
Information provided by (Responsible Party):
University Health Network, Toronto

Brief Summary:
For many individuals with Tourette syndrome (TS), available medications do not help with their symptoms, or cause significant side effects. Two small controlled trials have investigated the effect of oral delta-9-tetrahydrocannabinol (THC), a principal psychoactive ingredient of cannabis, in TS patients. While these trials have shown promising results, the effect sizes were not as large and consistent as those reported by patients with regards to inhaled cannabis (smoked or vaporized). Indeed, based on anecdotal evidence, patients have much greater improvement in their symptoms using inhaled cannabis than using cannabinoid pharmaceuticals. However, there have been no controlled trials of inhaled medical cannabis for TS to date. Furthermore, various medical cannabis products are authorized in Canada with different contents of THC and cannabidiol (CBD), another primary cannabinoid. No data exists regarding the dosing, efficacy and safety of these products in the treatment of TS. To gather such data, a double-blind, randomized, crossover pilot trial will be conducted to compare the efficacy and safety of three vaporized medical cannabis products with different THC and CBD contents, as well as placebo, in adults with TS. As well, the PK/PD profile of THC and CBD of the products will be assessed and correlated with tic symptoms

Condition or disease Intervention/treatment Phase
Tourette Syndrome Drug: Cannabis Phase 2

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description: There are four treatment schemes. All subjects will be randomized in a 1:1:1:1 ratio to one of the four treatment schemes. Participants will receive a single dose of each of the 3 cannabis products + placebo, with the order determine by their assigned treatment arm.
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Masking Description: The participants, investigators and analysts will be masked as to the treatment arm and product of each participant and visit. Only the pharmacists will be aware of the strain.
Primary Purpose: Treatment
Official Title: A Double-blind, Randomized, Placebo-controlled Crossover Pilot Trial of Medical Cannabis in Adults With Tourette Syndrome
Actual Study Start Date : January 15, 2018
Estimated Primary Completion Date : September 2018
Estimated Study Completion Date : September 2018

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
1
Three cannabis drug product formulations with different THC and CBD contents and placebo will be used in the following order: A (THC 10%, CBD <0.5%), B (THC 8.6%, CBD 8.6%), C (THC 0.6%, CBD 14%) and placebo D (THC <0.3%, CBD <0.3%).
Drug: Cannabis
THC 10%, CBD <0.5%
Other Name: Marijuana
Drug: Cannabis
THC 8.6%, CBD 8.6%
Other Name: Marijuana
Drug: Cannabis
THC 0.6%, CBD 14%
Other Name: Marijuana
2
Three cannabis drug product formulations with different THC and CBD contents and placebo will be used in the following order: B (THC 8.6%, CBD 8.6%), placebo D (THC <0.3%, CBD <0.3%), A (THC 10%, CBD <0.5%), C (THC 0.6%, CBD 14%).
Drug: Cannabis
THC 10%, CBD <0.5%
Other Name: Marijuana
Drug: Cannabis
THC 8.6%, CBD 8.6%
Other Name: Marijuana
Drug: Cannabis
THC 0.6%, CBD 14%
Other Name: Marijuana
3
Three cannabis drug product formulations with different THC and CBD contents and placebo will be used in the following order: C (THC 0.6%, CBD 14%), A (THC 10%, CBD <0.5%), placebo D (THC <0.3%, CBD <0.3%), B (THC 8.6%, CBD 8.6%).
Drug: Cannabis
THC 10%, CBD <0.5%
Other Name: Marijuana
Drug: Cannabis
THC 8.6%, CBD 8.6%
Other Name: Marijuana
Drug: Cannabis
THC 0.6%, CBD 14%
Other Name: Marijuana
4
Three cannabis drug product formulations with different THC and CBD contents and placebo will be used in the following order: placebo D (THC <0.3%, CBD <0.3%), C (THC 0.6%, CBD 14%), B (THC 8.6%, CBD 8.6%), A (THC 10%, CBD <0.5%).
Drug: Cannabis
THC 10%, CBD <0.5%
Other Name: Marijuana
Drug: Cannabis
THC 8.6%, CBD 8.6%
Other Name: Marijuana
Drug: Cannabis
THC 0.6%, CBD 14%
Other Name: Marijuana



Primary Outcome Measures :
  1. Modified Rush Video-Based Tic Rating Scale [ Time Frame: 10 minutes ]
    Can be used to assess changes in frequency and severity of tics


Secondary Outcome Measures :
  1. The Marijuana Effect Expectancy Questionnaire (MEEQ) [ Time Frame: 6 hours ]
    To assess tolerability of cannabis products


Other Outcome Measures:
  1. Area under the plasma concentration versus time curve of CBD and 11-OH-THC [ Time Frame: 6 hours ]
    Determine a temporal relationship between changes in THC/CBD plasma concentrations and tic severity

  2. Premonitory Urge for Tics Scale (PUTS) [ Time Frame: 1 hour ]
    Assesses the intensity of premonitory urges

  3. Clinical Global Impression- Improvement Scale (CGI-I) [ Time Frame: 1 hour ]
    Assesses how improved symptoms are after an intervention



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female adult, 18-65 years of age (inclusive) at the time of signing the informed consent.
  • The subject meets current DSM-5 diagnostic criteria for TS[6], diagnosed by a neuropsychiatrist with expertise in TS and related conditions.
  • YGTSS-TTS ≥16, frequency subscore = 5 and intensity subscore ≥ 2. In addition, tic free intervals do not last more than two minutes based on both self-reporting and observation by clinician at both screening and Week 0 (randomization). This requirement is for the purpose of minimizing the potential for floor effects given the relatively short window for assessing effect on symptoms in this single-dose trial.
  • The subject is able and willing to refrain from using any non-study cannabis during the screening and treatment phases of the study.
  • Females of childbearing potential (defined by menarche and not having undergone surgical sterilization/hysterectomy) must have a negative pregnancy test, must be practicing acceptable double-barrier methods of contraception (or can confirm abstinence at each scheduled visit), and must not be breast feeding.
  • Written informed consent must be obtained from the subject prior to the initiation of any protocol-required procedures.
  • The subject is able to comprehend and satisfactorily comply with the protocol requirements.

Exclusion Criteria:

  • • The subject and/or his/her family have a history of psychosis, schizophrenia or bipolar disorder.

    • Sexually active females of childbearing potential who will not commit to utilizing 2 of the approved birth control methods or who will not remain abstinent during the trial; Females who are breast-feeding and/or who have a positive serum pregnancy test result prior at the time of screening.
    • The subject represents a significant risk of committing suicide (current suicide plan or attempt in past 2 years) or committing homicide.
    • The subject has a history of serious head injury, seizure disorder, or developmental delay (intelligence quotient≤85).
    • The subject has either of: cardiovascular disease; respiratory disease such as chronic obstructive pulmonary disease (COPD) or lung cancer (asthma is not an exclusionary criterion); hepatitis.
    • The subject has a current or past history of substance abuse within the last 5 years, with the exception of cannabis.
    • The subject is using cannabis regularly for the treatment of TS.
    • The subject has any abnormal laboratory tests and vital sign results which in the investigator's judgment is medically significant and would impact the safety of the subject or the interpretation of the study results.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03247244


Contacts
Contact: Paul Sandor, MD 416-603-5794 paul.sandor@uhn.ca

Locations
Canada, Ontario
Toronto Western Hospital - Tourette Syndrome Neurodevelopmental Clinic Recruiting
Toronto, Ontario, Canada, M5T2S8
Contact: Ferdous Parveen    416-545-5484    ferdous.parveen@uhnresearch.ca   
Principal Investigator: Paul Sandor, MD         
Sub-Investigator: Elia Abi-Jaoude, MD         
Sponsors and Collaborators
University Health Network, Toronto
Investigators
Principal Investigator: Paul Sandor, MD University Health Network, Toronto

Responsible Party: University Health Network, Toronto
ClinicalTrials.gov Identifier: NCT03247244     History of Changes
Other Study ID Numbers: 14-7726
First Posted: August 11, 2017    Key Record Dates
Last Update Posted: May 3, 2018
Last Verified: July 2017

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Keywords provided by University Health Network, Toronto:
Cannabis
Tics
Tourette Syndrome

Additional relevant MeSH terms:
Tourette Syndrome
Syndrome
Marijuana Abuse
Disease
Pathologic Processes
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tic Disorders
Movement Disorders
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Genetic Diseases, Inborn
Neurodevelopmental Disorders